Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,649 matching trials from the live ClinicalTrials.gov search.
Not listed Phase 1 Interventional

Tocilizumab in Schizophrenia

NCT02874573
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Tocilizumab, Normal saline
Drug
Lead sponsor
Brian Miller
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Cognitive Disorders, Personality Disorders
Interventions
Physical activity intervention with peer support (PA+PS), Physical activity intervention without peer support (PA)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Reconnecting to Ourselves and Others in Virtual Meetings (ROOM)

NCT06360562
Conditions
Mood Disorders, Anxiety Disorders, Psychotic Disorders
Interventions
Resilience Training
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Charlestown, Massachusetts
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder, Psychosis
Interventions
Multi-element, team-oriented treatment
Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
15 Years to 35 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Conditions
Schizophrenia, Psychotic Disorders, Substance Abuse, Alcohol Abuse
Interventions
Risperidone Long Acting, oral risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
8
States / cities
Miami, Florida • Kansas City, Missouri • St Louis, Missouri + 5 more
Conditions
Schizophrenia
Interventions
Individual Placement and Support, Workplace Fundamentals Module, Brokered Vocational Rehabilitation, Oral risperidone, Skills training group
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Active, not recruiting No phase listed Observational Accepts healthy volunteers

AMP SCZ® Observational Study: PREDICT-DPACC

NCT05905003
Conditions
Clinical High Risk, Psychosis, Remission, Conversion
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
12 Years to 30 Years
Enrollment
2,617 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
17
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 13 more
Completed Not applicable Interventional Results available

Anti-Inflammatory Treatment of Schizophrenia

NCT01514682
Conditions
Schizophrenia
Interventions
Anti-inflammatory Combination Therapy, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Late Onset Schizophrenia, Delusional Disorder (Late Onset)
Interventions
Tau PET imaging scan
Diagnostic Test
Lead sponsor
Jeremy Koppel
Other
Eligibility
65 Years to 85 Years
Enrollment
16 participants
Timeline
2024 – 2027
U.S. locations
1
States / cities
Manhasset, New York
Conditions
Schizophrenia
Interventions
Ziprasidone 80-160 mg/d, Placebo, Ziprasidone 160 mg/d
Drug
Lead sponsor
Donald C. Goff, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
9
States / cities
Augusta, Georgia • Fall River, Massachusetts • Grand Rapids, Michigan + 6 more
Conditions
Schizophrenia and Related Disorders
Interventions
Active rTMS stimulation, Sham rTMS stimulation
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Conditions
Schizophrenia
Interventions
Placebo, Lu AF11167
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Glendale, California
Conditions
Schizophrenia
Interventions
SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Schizophrenia
Interventions
Online Family Education, Customary care
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Recruiting Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

NCT05184335
Conditions
Schizophrenia
Interventions
Brilaroxazine, Placebo
Drug · Other
Lead sponsor
Reviva Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
690 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Bentonville, Arkansas • Little Rock, Arkansas + 14 more
Conditions
Schizophrenia, Schizo Affective Disorder, Psychotic Disorders
Interventions
iTEST
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
La Jolla, California • Richardson, Texas
Conditions
Schizophrenia
Interventions
ITI-007, Risperidone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Culver City, California + 8 more
Conditions
Schizophrenia
Interventions
Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 61 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Costa Mesa, California • Long Beach, California • Oceanside, California + 14 more
Conditions
Schizophrenia, Psychopathology, Nicotine Dependence
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Conditions
Schizophrenia
Interventions
Aripiprazole and aripiprazole once-monthly, Paliperidone and paliperidone palmitate
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Conditions
Auditory Hallucination, Schizophrenia
Interventions
Transcranial direct-current stimulation (tDCS), Placebo
Device
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Psychosis
Interventions
ICBT Program
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
10 Years to 19 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Schizophrenia, Schizoaffective, Bipolar Disorder, Stress Disorders, Post-traumatic, Psychotic Disorders
Interventions
Psychiatric Advance Directives intervention
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Schizophrenia
Interventions
Computer-Based Cognitive Enhancement Training Program, Work Therapy Program
Behavioral
Lead sponsor
Yale University
Other
Eligibility
20 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut